Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has issued an update.
Thiogenesis Therapeutics Corp has announced the activation of its second clinical site in France for its Phase 2 trial of TTI-0102, targeting MELAS, a serious mitochondrial disorder. This expansion marks a significant milestone, with the company surpassing the patient enrollment threshold for a planned interim analysis. The trial aims to evaluate the safety and efficacy of TTI-0102, a promising candidate for treating mitochondrial dysfunction, potentially impacting the company’s positioning in the biopharmaceutical industry and offering hope for patients with unmet medical needs.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. It specializes in developing sulfur-based therapeutics aimed at treating serious pediatric and inherited mitochondrial diseases. The company is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S. Its lead product candidate, TTI-0102, is a prodrug designed to address challenges associated with first-generation thiol-based drugs.
Average Trading Volume: 33,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$37.05M
See more data about TTI stock on TipRanks’ Stock Analysis page.